Event Details

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer

Jun 01 2024 at 9:00 AM CDT


A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma

Abstract No. for Publication:


Session Title:

Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology